Industry pieces and lab reports show AI agents and tailored deep‑learning tools are moving from data curation to active roles in cancer research. One analysis outlined how autonomous AI agents are being integrated into cancer discovery and treatment design; Colorado State researchers separately used AI to redesign antibodies as intracellular fluorescent probes for live‑cell tracking of gene‑expression errors. Together they demonstrate AI’s expanding role from hypothesis generation to enabling new experimental reagents and accelerating target identification. Labs and R&D units must adapt validation pipelines and governance for AI‑designed biological tools.